This is an old revision of this page, as edited by BogBot (talk | contribs) at 06:46, 31 August 2011 (populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 06:46, 31 August 2011 by BogBot (talk | contribs) (populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) | This article does not cite any sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Perindopril/indapamide" – news · newspapers · books · scholar · JSTOR (October 2006) (Learn how and when to remove this message) |
| Combination of | |
|---|---|
| Perindopril | ACE inhibitor |
| Indapamide | diuretic |
| Clinical data | |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
Perindopril/indapamide is a combination therapy for the treatment of Essential hypertension.
Form and Composition
Each scored tablet contains 2 mg of perindopril tert-butylamine salt and 0.625 mg of indapamide.
Indication
Dosage and Administration
One tablet daily, preferably to be taken in the morning and before a meal.
Pharmacological Action
PRETERAX, a fixed combination of an ACE inhibitor and a chlorosulfamoyl diuretic, leads to additive synergy of the antihypertensive effects of the two constituents. Its pharmacological properties are derived from those of each of the components taken separately, in addition to those due to the additive synergistic action of the two constituents, when combined, on vascular endothelium, arteriolocapillary microcirculation, and the target organs of hypertension. Elderly patients: Normal dosage. Renal failure: Creatinine clearance (CrCl) >30 mL/min: no dosage modification. CrCl <30 ml/min: treatment contraindicated.
Contraindications
Absolute: Known allergy to perindopril, indapamide, or sulfonamides; history of Quincke's edema linked to previous ACE inhibitor therapy; severe renal failure; serious liver disorder; hyperkalemia; pregnancy; lactation. Relative: Combination therapy with lithium, potassium salts, potassium-sparing diuretics, and certain medicines which can cause heart rhythm disorders.
Side Effects
Asthenia, dizziness, headache, mood swings and/or sleep disturbances, cramps, hypotension, allergic reactions, skin rashes, gastrointestinal disorders, dry cough, dry mouth, risk of dehydration in the elderly and in patients suffering from heart failure; changes in blood test results may occur.
Warnings
Immunosuppressed patients. Hemodialysis: risk of anaphylactoid reaction during hemodialysis with polyacrylonitrile membranes. Liver impairment.
Precautions
Disorders of electrolyte balance, diabetes, gout, hypotension, or strict sodium-free diets, heart or renal failure, atherosclerosis, renal artery stenosis, elderly.
Drug Interactions
Not recommended: Combinations with lithium, potassium-sparing diuretics, potassium (salts), antiarrhythmic drugs which cause torsade de pointes, anesthetic drugs, cytostatic or immunosuppressive agents.
| Sympatholytic (and closely related) antihypertensives (C02) | |||||
|---|---|---|---|---|---|
| Sympatholytics (antagonize α-adrenergic vasoconstriction) | |||||
| Other antagonists |
| ||||
| |||||